Drug Profile
Research programme: ganglioside 2 antagonists - Mimetogen Pharmaceutcials
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator McGill University
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Small cell lung cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in Canada
- 21 Mar 2006 Preclinical trials in Small cell lung cancer in Canada (unspecified route)